111In-Diethylenetriaminepentaacetic acid-octreotide generally is used for the scintigraphic
imaging of neuroendocrine and other somatostatin receptor–positive tumors. On the basis of …

Peptide receptor–mediated radiotherapy of neuroendocrine and other somatostatin receptor–
positive tumors with radiolabeled somatostatin analogs has been applied in several …

Indium-111-diethylenetriaminepentaacetic Acid-d-phenylalanine1-octreotide (111In-DTPA-
octreotide) is a cyclic eight amino acid somatostatin analogue which is approved for gamma …

In most types of peptide receptor radionuclide therapy, the maximum activity dose that can
be administered is limited by high and persistent renal retention of the radiolabeled …

As scintigraphy with [111 In-DTPA 0] octreotide has become a standard technique in
analysing somatostatin receptor-receptor positive lesions such as neuroendocrine tumours …

The high renal uptake of radiolabeled somatostatin analogs is dose limiting. Lowering this
uptake permits higher radioactivity doses and, thus, tumor doses to be administered. We …

A promising application of radiolabeled somatostatin analogs is peptide receptor–targeted
radionuclide therapy of somatostatin receptor–expressing tumors. A suitable radionuclide is …

Purpose Peptide receptor radionuclide therapy using β-emitting radiolabelled somatostatin
analogues like DOTA, Tyr 3-octreotate shows beneficial results in patients suffering from …

Radiolabelled tumour receptor-binding peptides can be used for in vivo scintigraphic
imaging. Recently, the somatostatin analogue [Tyr 3] octreotide (d-Phe-c (Cys-Tyr-d-Trp-Lys …

The challenge for internal therapy is to deliver the highest possible dose to the tumor while
sparing normal organs from damage. Currently, the potential risk of kidney and red marrow …